SCHEMBL981566

SCHEMBL981566

N#Cc1cc2cc(Cl)cc(Cl)c2oc1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 9/20 1.00
USP2 O75604 1/20 0.54
POLB P06746 1/20 0.54
HPGD P15428 1/20 0.54
ALOX15 P16050 1/20 0.54
ALOX12 P18054 1/20 0.54
CASP1 P29466 1/20 0.54
CASP7 P55210 1/20 0.54
HSD17B10 Q99714 1/20 0.54
CA9 Q16790 2/20 0.53
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MAPT P10636 1/20 0.45
F12 P00748 3/20 0.44
MIF P14174 1/20 0.43
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7023546 0.79 GPR35 (0.62) GPR35CA9CA12CA1CA2
SCHEMBL7026581 0.78 GPR35 (0.61) GPR35USP2POLBHPGDALOX15
SCHEMBL8171798 0.74 GPR35 (0.58) GPR35USP2POLBHPGDALOX15
SCHEMBL3079094 0.73 GPR35 (1.00) GPR35HSD17B10CA9CA12CA1
SCHEMBL830270 0.71 CA12 (0.77) GPR35USP2POLBHPGDALOX15
SCHEMBL1367802 0.71 GPR35 (0.79) GPR35USP2POLBHPGDALOX15
SCHEMBL5867251 0.71 GPR35 (0.55) GPR35USP2POLBHPGDALOX15
SCHEMBL9586489 0.70 GPR35 (0.61) GPR35USP2POLBHPGDALOX15
SCHEMBL30110303 0.70 GPR35 (0.77) GPR35USP2POLBHPGDALOX15
SCHEMBL28572283 0.70 GPR35 (1.00) GPR35HPGDCA9ALDH1A1MIF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872029-B2 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states BOWEN J PHILLIP 2011-01-18 US disclosed
US-20090018167-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states Robinson, Thomas Philip (US) 2009-01-15 US disclosed
US-6906105-B2 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states BOWEN J PHILLIP (US) 2005-06-14 US disclosed
US-6462075-B1 USE OF CHALCONE AND ITS DERIVATIVES AS ANTITUMOR/ANTICANCER AGENTS AND TO TREAT A NUMBER OF CONDITIONS OR DISEASE STATES IN WHICH ANGIOGENESIS IS A FACTOR INCLUDING PSORIASIS, ACNE, ROSACEA, WARTS, ECZEMA, HEMANGIOMAS AND LYMPHANGIOGENESIS THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. 2002-10-08 US disclosed
US-4320133-A Penicillins and their antibacterial use SANDOZ LTD. (CH) 1982-03-16 US disclosed
EP-0003115-A1 Penicillins, per se and for use as antibacterially active antibiotics and their production SANDOZ AG (CH) 1979-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018167-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states FLT1, FLT4, VEGFA GPR35 2823/4885USP2 3911/4885POLB 2470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.